Companies › Shenzhen Ionova Life Sciences
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INV-1120 Selective small molecule for solid malignancies | – | Phase 1 | Cancer | Dec 2026 |
| INV-9956 | – | Phase 1 | Advanced Metastatic Castration Resistant Prostate Cancer | Jan 2028 |
| INV-6452 | – | Phase 1 | Breast Cancer (Locally Advanced or Metastatic) | Feb 2028 |
| INV-8989 KRAS G12D inhibitor | KRAS | Phase 1 | Advance Solid Tumors | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04443088 | INV-1120 | Phase 1 | Cancer | Oncology | Dec 2026 |
| NCT06609005 | INV-9956 | Phase 1 | Advanced Metastatic Castration Resistant Prostate Cancer | Oncology | Jan 2028 |
| NCT07612891 | INV-6452 | Phase 1 | Breast Cancer (Locally Advanced or Metastatic) | Oncology | Feb 2028 |
| NCT07610798 | INV-8989 | Phase 1 | Advance Solid Tumors | Oncology | May 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.